- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04094155
Retinal Vessel Analysis (rGA) at the Patient Bed in the Context of Non-traumatic Subarachnoid Haemorrhage
A subarachnoid hemorrhage occurs in about 10 out of 100,000 people each year. This bleeding leads to irritation and constriction of blood vessels in the brain (vasospasm) in two out of three people affected within four to 21 days and thus to reduced blood flow. This can lead to a stroke and serious damage. In order to be able to diagnose and treat a constriction of the blood vessels at an early stage, there are various examination methods which, however, have various disadvantages such as radiation exposure of the patient, low sensitivity or high effort. Therefore, the prediction and timely therapy of vascular constrictions is currently only successful in a few cases before the reduced blood flow has already led to irreversible damage.
The aim of this study is to investigate whether the so-called retinal vascular analysis can be used in addition to previous standard examinations for the early detection of diseases of the cerebral blood circulation. This method has few side effects and has been successfully used for 50 years to examine the blood circulation in the eye.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Aachen, Alemania, 52074
- Reclutamiento
- Uniklinik RWTH Aachen, Klinik für Neurochirurgie
-
Contacto:
- Gerrit A Schubert, Prof. Dr.
- Número de teléfono: +49 2418088480
- Correo electrónico: gschubert@ukaachen.de
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Female or male patient, age ≥ 18 years
- Inpatient stay in the clinic
- Written informed consent for participation in the study prior to beginning of treatment
- Written consent for further evaluation of the images and for the scientific publication of the study results
- Non-traumatic subarachnoid haemorrhage confirmed by computer tomography or magnetic resonance tomography or cerebrospinal fluid puncture (collection of nerve water from the lower part of the lumbar spine
Exclusion Criteria:
- Female or male patient < 18 years
- Pregnancy, Lactation
- Lack of written consent to participate in the study and to further evaluate the image material collected
- Known allergy to MS eye drops (active substance: phenylephrine/tropicamide
- Narrow chamber angle, narrow angle glaucoma, Terson syndrome (if it makes retinal vascular imaging impossible
- Persons in a dependency or employment relationship with the investigator
- Persons who are accommodated in a facility by judicial or administrative order
- Receipt and intake of a study drug within the last 30 days
- Supine position in bed
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Retinal fundoscopy
Retinal vascular analysis by retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
|
Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clinical Progression of Delayed cortical ischemia
Periodo de tiempo: 21 days
|
Delayed cortical ischemia as ischemia in cranial computer tomography or cranial magnetic resonance tomography that occurred later than 24 hours after admission to hospital
|
21 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Occurrence of delayed ischemic neurological deficit (DIND)
Periodo de tiempo: 21 days
|
21 days
|
|
|
Angiographic vasospasm
Periodo de tiempo: 7 days
|
Occurence of an angiographic vasospasm measured by:
|
7 days
|
|
Metabolic deficiency supply
Periodo de tiempo: 21 days
|
Measured as change in lactate-pyruvate ratio in microdialysis
|
21 days
|
|
Metabolic deficiency supply
Periodo de tiempo: 21 days
|
Measured as change in reduction in parenchymal oxygen partial pressure measurement
|
21 days
|
|
Relative underperfusion
Periodo de tiempo: 21 days
|
Measured by Perfusion-Computer-Tomography
|
21 days
|
|
Objective degree of recovery
Periodo de tiempo: 3 Month
|
Measured by Glasgow-Outcome-Scale; Scale by which patients who have experienced brain damage can be divided into 5 groups that allow to describe the degree of recovery in a standardized and objective manner (1: death; 2: vegetative condition, the patient is unresponsive.
The higher cognitive functions are extinguished; 3: severe disability, the patient is conscious, but cannot cope with normal everyday activities without help; 4: moderate disability, the patient can live largely independently, but is not able to pursue a normal working life; 5: light to no handicap, the neurological, physical, and psychological deficits are so low that the patient can participate normally in social and economic activities)
|
3 Month
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Gerrit A Schubert, Prof. Dr., Principal Investigator
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 14-061
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre retinal vascular analysis
-
Fondation Ophtalmologique Adolphe de RothschildTerminadoEnfermedad de HortonFrancia
-
Francesco De CobelliReclutamientoHepatectomía | Ablación del hígado | Resección del hígado | Metástasis al hígado colorrectal (CRLM)Italia
-
Vanderbilt University Medical Center4DMedicalTerminado
-
Medical University of SilesiaPH DOCTOR N&D Wiśniewscy S.K.A.TerminadoEnvejecimiento de la piel | FotoenvejecimientoPolonia
-
Benha UniversityReclutamientoObesidad | Diabetes | Ayuno | Ayuno, Intermitente | Hipoglucemia en ayunasEgipto
-
Stanford UniversityBascom Palmer Eye InstituteTerminadoDegeneración macular | Drusas retinalesEstados Unidos
-
The Hospital for Sick ChildrenReclutamientoEnfermedad genética | Enfermedad hereditariaCanadá
-
Jean-Claude TardifMontreal Heart Institute; Polytechnique MontréalTerminado
-
Second Sight Medical ProductsTerminadoRetinitis pigmentosaEstados Unidos
-
The First Affiliated Hospital with Nanjing Medical...DesconocidoDegeneración macular | La degeneración macular relacionada con la edad | AMDPorcelana